Tolperisone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tolperisone: From Muscle Spasm to Laubry-Pezzi Syndrome
One-Sentence Summary
Tolperisone is a centrally-acting, voltage-gated sodium channel blocker used clinically as a muscle relaxant (specific formally-approved indication text is not available in this evidence pack). The TxGNN model predicts it may be effective for Laubry-Pezzi Syndrome (a congenital cardiac malformation involving ventricular septal defect with overriding aorta), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure topological/embedding-similarity output from the model, and the evidence pack’s own mechanistic review found no known pathophysiological link between the drug and this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Muscle spasm/spasticity (per drug class description in evidence pack; formal approved indication text not available) |
| Predicted New Indication | Laubry-Pezzi Syndrome |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is flagged as a Blocking/High-severity data gap in this evidence pack (DG001, DG002). Based on the mechanistic notes embedded in the repurposing rationale, tolperisone is described as a centrally-acting, voltage-dependent sodium channel blocker functioning as a muscle relaxant — this is the only characterization available, as no formal MOA record or approved-indication text could be extracted.
Laubry-Pezzi syndrome is a congenital structural cardiac defect (ventricular septal defect with aortic override), unrelated in etiology or pathophysiology to skeletal muscle tone regulation. The evidence pack’s own mechanistic review explicitly states there is no known pathophysiological relationship between tolperisone’s sodium-channel-blocking action and this congenital cardiac malformation — the prediction is described as “purely a TxGNN topological prediction, with no supporting literature or trials.”
Given the absence of a plausible biological rationale, absence of any clinical or preclinical evidence, and the very high TxGNN score being unaccompanied by corroborating data, this candidate should be treated as a low-confidence model artifact rather than a scientifically grounded repurposing hypothesis at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Tolperisone currently has no registration records in the India regulatory dataset (0 licenses, market status: Not Marketed). No product/dosage-form/indication information is available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug-drug interaction data are all currently unavailable — flagged as Blocking data gap DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Laubry-Pezzi syndrome, TxGNN score 99.92%) has evidence level L5 — no clinical trials, no supporting literature, and no plausible mechanistic link, as confirmed by the evidence pack’s own rationale review. This pattern holds across all 10 top-ranked candidates for this drug: none advance past Evidence Level L4/L5, and where literature was retrieved (e.g., “heart disease,” “disorder of fucoglycosan synthesis”), it was assessed as irrelevant co-occurrence noise or indexing mismatches rather than supportive evidence. Combined with the drug’s non-marketed status in India (0 registrations) and missing MOA/safety data, there is currently no basis to proceed beyond Hold.
To proceed, the following is needed:
- TFDA/CDSCO package insert with formal warnings and contraindications (DG001 — Blocking, required before any S1 safety screening)
- Confirmed mechanism of action from DrugBank API query (DG002)
- Original approved-indication text for the drug (currently unavailable)
- Re-indexed literature review to correctly attribute the tolperisone/Parkinson’s-disease MMP-9 signal (PMID 38513594) to its actual disease category, since it was misfiled under an unrelated candidate and may warrant separate evaluation
- Any preclinical or mechanistic data specifically connecting sodium-channel blockade to congenital cardiac or craniofacial syndromes before this candidate can be reconsidered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.